Loading...
•
Dec 31, 2023
Novanta Q4 2023 Earnings Report
Novanta reported revenue and profit performance above expectations in a dynamic operating environment, with record revenue, adjusted gross margin, and adjusted EBITDA for the full year.
Key Takeaways
Novanta's Q4 2023 saw a slight decrease in revenue compared to Q4 2022, but the company delivered revenue and profit performance above expectations. Full year 2023 results included record revenue, adjusted gross margin, and adjusted EBITDA.
GAAP Revenue was $211.6 million, a decrease of 3.1% year-over-year.
GAAP Operating Income was $21.7 million, compared to $26.8 million in Q4 2022.
GAAP Net Income was $12.5 million, compared to $15.3 million in Q4 2022.
Adjusted EBITDA was $45.3 million, compared to $46.1 million in Q4 2022.
Novanta
Novanta
Novanta Revenue by Segment
Revenue by Segment
Medical Solutions Revenue
CapyFin.com Forward Guidance
For the full year 2024, the Company expects GAAP revenue of approximately $975 million to $1 billion. The Company expects Adjusted Gross Profit Margin to be approximately 46.0% to 47.0%. The Company expects Adjusted EBITDA to be in the range of $215 million to $225 million and Adjusted Diluted EPS to be in the range of $3.10 to $3.35.
Positive Outlook
- Innovative products to help customers differentiate in their end markets.
- Positioned in secular high-growth markets.
- Right technologies.
- World-class team dedicated and aligned to the Novanta mission.
- Attractive financial framework and sustaining long-term shareholder value.
Challenges Ahead
- Assumes no significant changes in foreign exchange rates.
- Inherent difficulty in forecasting and quantifying certain amounts that are necessary for reconciliations.
- Acquisitions and related expenses.
- Impact of purchase price allocations for recently completed acquisitions.
- Future changes in the fair value of contingent considerations.